LEGISLATIVE PHARMACOECONOMIC STANDARD NEED NOT PRECLUDE RIGOROUS STUDIES -- FDA's TEMPLE; DATA BASE ANALYSES ARE NOT SUITABLE FOR COST-EFFECTIVENESS CLAIMS
The attempt by Congress to set a new legislative standard for FDA oversight of pharmacoeconomic claims should not discourage companies from performing rigorous analyses of their products, Center for Drug Evaluation & Research Associate Director for Medical Policy Robert Temple, MD, told a meeting of the Food & Drug Law Institute Sept. 4 in Washington, D.C.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth